2 Information about erenumab

Marketing authorisation indication

2.1 Erenumab (Aimovig, Novartis) is indicated for 'prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of erenumab is £386.50 per 70 mg or 140 mg injection (excluding VAT, BNF online, accessed November 2020). The company has a commercial arrangement. This makes erenumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)